An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate CancerMichael H. Brave, Julia A. Beaver, Chana Weinstock et al.|Clinical Cancer Research|2020Cited by 29
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trialsJaleh Fallah, Harpreet Singh, Bellinda L. King‐Kallimanis et al.|The Lancet Oncology|2021Cited by 15
Data from An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate CancerMichael A. Brave, Julia A. Beaver, Chana Weinstock et al.|Unknown|2023Cited by 0
Data from An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate CancerMichael A. Brave, Julia A. Beaver, Chana Weinstock et al.|Unknown|2023Cited by 0
Supplementary Tables S1-S7 from An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate CancerMichael A. Brave, Julia A. Beaver, Chana Weinstock et al.|Unknown|2023Cited by 0